PHARMACOLOGICAL APPROACHES TARGETTING INFLAMMATORY PATHWAY OF CARDIOVASCULAR COMORBIDITIES

Cardiovascular event is the general term used to indicate numerous heart diseases which are related to fat deposition and arthrosclerosis which accounts for higher mortality rates. Co-occurrence of obesity, hyperglycemia and cardiovascular disease is the major health concern resulting in increased mortality. It is well known that obesity leads to cardiovascular mortality independent of other factors. Obesity activates JNK pathway through inflammatory response which is the hallmark of insulin resistance. Hyperglycemia and obesity promotes systemic inflammation. Inflammatory response remains the key factor for initiation and progression of cardiovascular disease and co morbid conditions. Hence focusing on the inflammatory mediator pathway will guide in individualizing therapeutic regimen to alleviate the disease. Existing hyperlipidiemic drugs HMG CoA Reductase inhibitors, Peroxisome proliferator activated receptors and Fibrates, Cholesterol absorption inhibitors and synthetic hypoglycemic agents GLP-1 agonist, Biguanide, DPP-4 inhibitors are focused in management because of their anti-inflammatory and insulin sensitizing mechanism which has positive impact on patient’s life.

Keywords: Arthrosclerosis, Cardiovascular disease, Inflammation, Insulin resistance, Obesity.